Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25231629 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL4911952 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL14966102 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL25336996 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL2413045 | 0.98 | TSHR (0.54) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL8386491 | 0.91 | TSHR (0.73) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL15923909 | 0.91 | TSHR (0.73) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL678273 | 0.91 | TSHR (0.73) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL19040831 | 0.91 | TSHR (0.65) | TSHRFAAHTRPV1ALDH1A1HTT | |
| SCHEMBL10584770 | 0.91 | TSHR (0.73) | TSHRFAAHTRPV1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943532-B2 | Iminosugars and methods of treating viral diseases | EMERGENT VIROLOGY LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170304333-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | EMERGENT VIROLOGY LLC (US) | 2017-10-26 | — | — | US | disclosed |
| US-9579334-B2 | Iminosugars and methods of treating viral diseases | EMERGENT VIROLOGY LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160243096-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | EMERGENT VIROLOGY LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243097-A1 | METHODS OF TREATING POXVIRAL INFECTIONS | EMERGENT VIROLOGY LLC (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2398321-B1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORP (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2400843-B1 | IMINOSUGARS AND METHODS OF TREATING ARENAVIRAL INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| CN-102625801-B | Methods of treating poxvirus infections | UNITED THERAPEUTICS CORP. (US) | 2015-09-09 | — | — | CN | disclosed |
| US-20150224128-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-9044470-B2 | Iminosugars and methods of treating viral diseases | UNITED THERAPEUTICS CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| WO-2010096764-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0765314-B1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243096-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | EIF2AK2, ENGASE, MANBA | TSHR 4202/4885FAAH 2070/4885TRPV1 4026/4885 |
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | TSHR 180/4885FAAH 111/4885TRPV1 80/4885 |
| US-20160243097-A1 | METHODS OF TREATING POXVIRAL INFECTIONS | DPM1, EIF2AK2, DERA | TSHR 4639/4885FAAH 2753/4885TRPV1 3659/4885 |
| US-20150224128-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | GBA1, UGCG, HAVCR2 | TSHR 3979/4885FAAH 720/4885TRPV1 4350/4885 |
| US-20170304333-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | GBA1, UGCG, HAVCR2 | TSHR 3979/4885FAAH 720/4885TRPV1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.